GlassScriptPhysician profile
Amyn Hirani
NPI 1841401940
$67,992.77
in general payments reported to CMS, 2019-2025
40 companies · $1,537 in 2025
The $1,537 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $12K · 2021: $15K · 2022: $12K · 2023: $10K · 2024: $2,063 · 2025: $1,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,425 · Food and Beverage: $4,615 · Education: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,425.00 |
| Food and Beverage | $4,614.84 |
| Education | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $37,575.07 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Mallinckrodt Enterprises LLC | $14,055.12 | 2019 | |
| Mallinckrodt Hospital Products INC. | $11,302.62 | 2020-2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $984.34 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $643.85 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Regeneron Healthcare Solutions, INC. | $484.89 | 2019-2025 | Dupixent |
| Genzyme Corporation | $430.68 | 2021-2025 | |
| Grifols USA, LLC | $391.01 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Ani Pharmaceuticals, INC. | $296.42 | 2023-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $226.08 | 2023-2025 | Glassia |
| Insmed, INC. | $191.82 | 2019-2025 | Brinsupri, Arikayce |
| Merck Sharp & Dohme LLC | $126.49 | 2023-2025 | Winrevair, Keytruda |
| Janssen Pharmaceuticals, INC | $124.74 | 2019 | |
| Pulmonx Corporation | $103.37 | 2023-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Amgen INC. | $87.51 | 2020-2024 | Tezspire |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $80.17 | 2021-2023 | Yupelri |
| Baxter Healthcare | $75.59 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Genentech USA, INC. | $75.04 | 2019-2025 | Tecentriq, Alecensa, Itovebi |
| Eisai INC. | $70.99 | 2019-2025 | |
| Shire North American Group INC | $64.24 | 2019 | |
| Verona Pharma, INC. | $63.60 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $57.48 | 2024 | |
| United Therapeutics Corporation | $54.57 | 2023-2025 | Tyvaso, Tyvaso |
| Ipsen Biopharmaceuticals, INC | $54.24 | 2020-2021 | |
| Viatris Specialty LLC | $37.76 | 2025 | Yupelri |
| Abbvie INC. | $33.56 | 2021 | |
| Alexion Pharmaceuticals, INC. | $31.70 | 2022 | |
| Jazz Pharmaceuticals INC. | $30.99 | 2022 | |
| Daiichi Sankyo INC. | $29.27 | 2025 | Enhertu |
| Nabriva Therapeutics, Plc | $27.38 | 2020 | |
| Csl Behring | $23.83 | 2023 | Hizentra |
| Lilly USA, LLC | $22.73 | 2025 | Zepbound |
| Inari Medical, INC. | $19.66 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| E.R. Squibb & Sons, L.L.C. | $18.84 | 2021 | |
| Allergan, INC. | $17.75 | 2020 | |
| Axsome Therapeutics, INC. | $16.36 | 2024 | Sunosi |
| Seagen INC. | $15.98 | 2021 | |
| Adma Biomanufacturing LLC | $15.87 | 2022 | |
| La Jolla Pharmaceutical Company | $15.59 | 2023 | Giapreza |
| Melinta Therapeutics, LLC | $15.57 | 2023 | Vabomere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amyn Hirani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.